138 related articles for article (PubMed ID: 38415054)
1. Rivaroxaban in the treatment of livedoid vasculopathy: A long-term retrospective study.
Deng S; Liu Y; Huang J; Shi W
JAAD Int; 2024 Mar; 14():36-38. PubMed ID: 38415054
[No Abstract] [Full Text] [Related]
2. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
Lancet Haematol; 2016 Feb; 3(2):e72-9. PubMed ID: 26853646
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale.
Drabik A; Hillgruber C; Goerge T
JMIR Res Protoc; 2014 Dec; 3(4):e73. PubMed ID: 25500152
[TBL] [Abstract][Full Text] [Related]
4. Excellent Long-term Clinical Response to Rivaroxaban in Livedoid Vasculopathy: A Retrospective Study.
Morgado-Carrasco D; Ibaceta J; Iranzo P; Bosch-Amate X; Mascaró-Galy JM
Actas Dermosifiliogr; 2023 Feb; 114(2):183-185. PubMed ID: 36115384
[No Abstract] [Full Text] [Related]
5. Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.
Ramphall S; Rijal S; Prakash V; Ekladios H; Mulayamkuzhiyil Saju J; Mandal N; Kham NI; Shahid R; Naik SS; Venugopal S
Cureus; 2022 Aug; 14(8):e28485. PubMed ID: 36051980
[TBL] [Abstract][Full Text] [Related]
6. Associations between coagulation factors and livedoid vasculopathy and the efficacy and safety of rivaroxaban in patients with livedoid vasculopathy: a retrospective study.
Zhao C; Yu M; Cheng X; Li S; Feng S
Clin Exp Dermatol; 2024 Jan; ():. PubMed ID: 38287670
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban for treatment of livedoid vasculopathy: A systematic review.
Gao Y; Jin H
Dermatol Ther; 2021 Sep; 34(5):e15051. PubMed ID: 34197012
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy.
Seguí M; Llamas-Velasco M
Front Med (Lausanne); 2022; 9():993515. PubMed ID: 36569162
[TBL] [Abstract][Full Text] [Related]
9. Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.
Han Y; Tu P
Front Immunol; 2022; 13():1008392. PubMed ID: 36389811
[TBL] [Abstract][Full Text] [Related]
10. Treatment application of rivaroxaban in Chinese patients with livedoid vasculopathy.
Chen W; Fan L; Wang Y; Deng X
J Pain Res; 2017; 10():621-624. PubMed ID: 28360530
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of livedoid vasculopathy with rivaroxaban.
Evans JM; Jensen JD; Sami N
JAAD Case Rep; 2015 Nov; 1(6):340-1. PubMed ID: 27051773
[No Abstract] [Full Text] [Related]
12. Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.
Gao Y; Jin H
J Dermatolog Treat; 2022 Feb; 33(1):178-183. PubMed ID: 32116074
[TBL] [Abstract][Full Text] [Related]
13. Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin.
Abou Rahal J; Ishak RS; Otrock ZK; Kibbi AG; Taher AT
J Thromb Thrombolysis; 2012 Nov; 34(4):541-4. PubMed ID: 22592843
[TBL] [Abstract][Full Text] [Related]
14. Successful Treatment of Painful Cutaneous Vasculopathy With Rivaroxaban in a Patient With Systemic Lupus Erythematosus.
Leisenring NH; Rogers JL; Telloni S; Mansoori P; Al-Rohil RN; Marano AL
J Drugs Dermatol; 2020 May; 19(5):544-546. PubMed ID: 32484618
[TBL] [Abstract][Full Text] [Related]
15. Livedoid vasculopathy with underlying subcutaneous necrotizing venulitis in an asymptomatic hepatitis B virus carrier: is livedoid vasculopathy a true nonvasculitic disorder?
Ishibashi M; Miyamoto J; Nagasaka T; Chen KR
Am J Dermatopathol; 2009 May; 31(3):293-6. PubMed ID: 19384073
[TBL] [Abstract][Full Text] [Related]
16. Dermoscopic features of livedoid vasculopathy.
Hu SC; Chen GS; Lin CL; Cheng YC; Lin YS
Medicine (Baltimore); 2017 Mar; 96(11):e6284. PubMed ID: 28296736
[TBL] [Abstract][Full Text] [Related]
17. Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment.
Lee JS; Cho S
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):e176-e178. PubMed ID: 31793049
[No Abstract] [Full Text] [Related]
18. Adalimumab in Treating Refractory Livedoid Vasculopathy.
Huang XW; Zheng HX; Wang ML; He WM; Feng MX; Zeng K; Li L
Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455298
[TBL] [Abstract][Full Text] [Related]
19. Penile Livedoid Vasculopathy: First Reported Case.
Hallak A; Bennett W; Tanbir MA; Donthamsetty SR; Vincent B
Case Rep Vasc Med; 2023; 2023():6920383. PubMed ID: 37440957
[TBL] [Abstract][Full Text] [Related]
20. Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy.
Juan WH; Chan YS; Lee JC; Yang LC; Hong HS; Yang CH
Br J Dermatol; 2006 Feb; 154(2):251-5. PubMed ID: 16433793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
